Compare LKFN & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | ARDX |
|---|---|---|
| Founded | 1872 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2009 | 2014 |
| Metric | LKFN | ARDX |
|---|---|---|
| Price | $60.00 | $5.56 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $67.00 | $15.14 |
| AVG Volume (30 Days) | 159.5K | ★ 3.0M |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | ★ 10.47 | N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | $985,000.00 | ★ $2,607,000.00 |
| Revenue This Year | $15.50 | $37.75 |
| Revenue Next Year | $5.51 | $34.24 |
| P/E Ratio | $57.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $54.36 | $3.54 |
| 52 Week High | $69.38 | $8.40 |
| Indicator | LKFN | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 53.19 | 36.36 |
| Support Level | $58.03 | $5.49 |
| Resistance Level | $60.94 | $6.23 |
| Average True Range (ATR) | 1.35 | 0.26 |
| MACD | 0.01 | -0.10 |
| Stochastic Oscillator | 81.49 | 20.35 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare. The company's revenue is derived from the business of banking.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.